News | March 09, 2022
SII’s Covovax approved for 12-17 years age group
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)